Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The enamel hydroxyapatite mineralization process is the biological pathway by which ameloblast cells secrete enamel matrix proteins (including amelogenin, ameloblastin, and enamelin), guiding the nucleation and elongation of hydroxyapatite (HAP) crystals to form the hard outermost tissue of teeth[1][2][3][4]. The result is a highly organized arrangement of hydroxyapatite rods (prisms) that confer the remarkable mechanical properties of enamel. This is a strictly cell-mediated, non-collagenous mineralization; it differs from bone or dentin formation because the enamel lacks living cells after maturation, making it uniquely non-regenerative—once damaged, natural repair is limited[1][2][3][4]. Preventive and reparative therapies focus on promoting remineralization (with agents such as fluoride or synthetic nano-hydroxyapatite) to encourage the chemical deposition of new mineral capable of integrating with existing enamel[5][6].
Fluoride promotes formation of fluorapatite, making enamel more acid-resistant. Calcium and phosphate supplementations assist in remineralization and hydroxyapatite lattice repair.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enamel hydroxyapatite mineralization process.